Alexander Perl is an Oncology physician affiliated with University of Pennsylvania. OpenAlex indexes 415 publications with 16,098 citations (h-index 55); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce St
15 Penn Tower
Philadelphia, PA 19104
Telephone
215-662-3914Registry record last updated 19 Aug 2013.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year202516 payments$14,046openpaymentsdata.cms.gov ↗
- Syndax Pharmaceuticals, Inc.Program year20257 payments$12,513openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Europe GmbHProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
44.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor44.2%Acyclovir100%Part D≥18 patientsCancer & immunology
44.2%Kinase inhibitor15.8%Sprycel100%Part D<11 patientsBCL-2 Inhibitor15.8%Venclexta100%Part D<11 patients+ 1 more class in this area
Anti-infectives
11.6%Fluoroquinolone Antibacterial11.6%Levofloxacin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2014 per NIH RePORTER. The latest:
- mTOR Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
University of Pennsylvania
FY2014$172,368K23CA141054 - mTOR Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
University of Pennsylvania
FY2013$172,368K23CA141054 - mTOR Inhibition as a Therapeutic Strategy for Acute Myeloid Leukemia
University of Pennsylvania
FY2012$172,368K23CA141054
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology
2024 - Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Journal of Clinical Oncology
2024 - Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Harold Feldman, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”